ERBB2 and non-small cell lung carcinoma: Furthermore, there is a lack of research reporting comprehensive HER2 missense alteration subtypes and their clinical responses to HER2-targeted TKIs in NSCLC, with a focus on highlighting their molecular features to provide clinical reference as a benchmark.